Dermatology Medical News about antitumour immunity

Your Unread Messages

See All

Tracy Hampton, PhD

Clinical Trial Watch

Cytarabine Plus Methotrexate Improves Remission Rates in Patients with Primary CNS Lymphoma

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

Hedgehog Pathway Inhibitor Shrinks Medulloblastoma

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity
British Journal of Dermatology, 11/02/09

Mitsui H et al. – I.d. injections of rR9–containing immunogenic Ag without adjuvants simultaneously induce dual immunological effects: the induction of Tc1– and Th1–dominant immune responses, and the induction of inflammatory and CTL–mediated immune responses at the injection area by expressing Ag epitopes on MHC class I molecules as targets. This simple vaccination approach with R9–PTD–containing fusion proteins might be useful as prophylactic immunotherapy for cancer or infectious diseases.

<< Previous
Severe exacerbation of multiple self-healing squamous epithelioma...

Next >>
Topical sodium cromoglicate relieves allergen- and...